In a previous study published by our lab, we reported that dual nivolumab-ipilimumab treatment increased production of IFN-γ more substantially than single agent alone in oesophageal adenocarcinoma patient-derived T cells ex vivo (18). Here, IFNG is linked to esophageal adenocarcinoma.